Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer

From MaRDI portal
Publication:70258

DOI10.2307/2531628zbMath0715.62242OpenAlexW2076108528WikidataQ48901121 ScholiaQ48901121MaRDI QIDQ70258

John O'Quigley, Lloyd Fisher, John O'Quigley, Lloyd Fisher, Margaret S. Pepe

Publication date: March 1990

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.2307/2531628




Related Items (only showing first 100 items - show all)

Sequential Monte Carlo for Bayesian sequentially designed experiments for discrete dataPatient-specific dose finding in phase I clinical trialsDose‐finding methods for Phase I clinical trials using pharmacokinetics in small populationsA note on continual reassessment methodOptimal sequential designs in phase I studiesContinual Reassessment Method for Partial OrderingDesigns for Single- or Multiple-Agent Phase I TrialsPhase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian DesignNovel Bayesian Adaptive Designs and Their Applications in Cancer Clinical TrialsAn application of reinforced urn processes to determining maximum tolerated doseReview of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast EnrollmentSEQUENTIAL METHODS IN CLINICAL TRIALS*Designs foe phase i cancer clinical trials with differentiation of graded toxicityA Latent Contingency Table Approach to Dose Finding for Combinations of Two AgentsThe role of minimal sets in dose finding studiesEfficiency of bridging between related dose finding studiesTime-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trialSequential method of estimating the LD50 using a modified up-and-down ruleA new design of the continual reassessment methodA novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and \(\epsilon\)-taperingImpact of different model structure and prior distribution in continual reassessment methodEscalation with overdose control using ordinal toxicity grades for cancer phase I clinical trialsMethodology and application of adaptive and sequential approaches in contemporary clinical trialsNumber of patients per cohort and sample size considerations using dose escalation with overdose controlA Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in Phase I clinical trialsUnnamed ItemAdaptive isotonic estimation of the minimum effective and peak doses in the presence of covariatesStochastic approximation and modern model-based designs for dose-finding clinical trialsContinual reassessment and related dose-finding designsDose finding with escalation with overdose control (EWOC) in cancer clinical trialsBayesian models and decision algorithms for complex early phase clinical trialsApproximate dynamic programming and its applications to the design of Phase I cancer trialsA new look at evaluating MTD designs in cancer researchA note on the robustness of the continual reassessment methodAdaptive Bayesian compound designs for dose finding studiesBayesian phase I/II adaptively randomized oncology trials with combined drugsThe adaptive accelerated biased coin design for phase I clinical trialsBayesian data augmentation dose finding with continual reassessment method and delayed toxicityIncorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose controlAdaptive clinical trial designs for phase I cancer studiesCumulative cohort design for dose-findingA Statistical Framework for Quantile Equivalence Clinical Trials with Application to Pharmacokinetic Studies that Bridge from HIV‐Infected Adults to ChildrenRandom-effects meta-analysis of phase I dose-finding studies using stochastic process priorsDynamic calibration of pharmacokinetic parameters in dose-finding studiesContinual reassessment method with multiple toxicity constraintsBook ReviewsOn the consistency of the continual reassessment method with multiple toxicity constraintsIncorporating Individual and Collective Ethics into Phase I Cancer Trial DesignsA class of designs for Phase I cancer clinical trials combining Bayesian and likelihood approachesDesign efficiency in dose finding studiesAdaptive designs for selecting drug combinations based on efficacy-toxicity responseConvergence properties of sequential Bayesian \(D\)-optimal designsUtility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II TrialsSimple benchmark for complex dose finding studiesOptimal adaptive generalized Pólya urn design for multi-arm clinical trialsThe treatment versus experimentation dilemma in dose finding studiesDose-Finding Based on Efficacy-Toxicity Trade-OffsA Semiparametric Sequential Algorithm for Estimation of Dose–Response CurveUnnamed ItemAdaptive designs for binary treatment responses in phase III clinical trials: controversies and progressEthical considerations concerning treatment allocation in drug development trialsA Curve‐Free Method for Phase I Clinical TrialsThe Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood ApproachSequential Designs for Phase I Clinical Trials with Late‐Onset ToxicitiesTheoretical study of the continual reassessment methodAdaptive designs for dose-finding based on efficacy-toxicity responseDose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified ApproachDesigns for Phase I Clinical Trials with Multiple Courses of Subjects at Different DosesStatistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical TrialsA bayesian predictive approach to sequential search for an optimal dose: Parametric and nonparametric modelsMultivariate Markov models for the conditional probability of toxicity in phase II trialsIncoherent dose-escalation in phase I trials using the escalation with overdose control approachThe Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood ApproachA Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic AgentsImplementation of a Bayesian Design in a Dose‐Escalation Study of an Experimental Agent in Healthy VolunteersSequential Methods in Multi-Arm Clinical TrialsescalationAnalysis of ``learn-as-you-go (LAGO) studiesUnifying CRM and EWOC designs for phase I cancer clinical trialsDose-Finding Based on Feasibility and Toxicity in T-cell Infusion TrialsDose-Finding Designs for HIV StudiesMonitoring the Rates of Composite Events with Censored Data in Phase II Clinical TrialsOn the Use of Nonparametric Curves in Phase I Trials with Low Toxicity ToleranceCurve-Free and Model-Based Continual Reassessment Method DesignsA Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment MethodDirected Walk Designs for Dose-Response Problems with Competing Failure ModesOn optimal designs for clinical trials: an updated reviewA study of the probit model with latent variables in Phase I clinical trialsOptimal Bayesian-feasible dose escalation for cancer phase I trialsFlexible link continual reassessment methods for trivariate binary outcome phase I/II trialsOperating characteristics of the standard phase I clinical trial design.Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trialsOptimal designs for dose-escalation trials and individual allocations in cohortsUsing a one-parameter model to sequentially estimate the root of a regression function.A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within PatientsUsing Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose RegimesBayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds RatiostrialrA conversation with Nancy FlournoyTarget toxicity design for phase I dose-finding




This page was built for publication: Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer